{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-essential-documents-after-trial-ich-e6-section-8”
},
“headline”: “SOP for Essential Documents After Trial (ICH E6 §8)”,
“description”: “This SOP defines the procedures for collecting, filing, and archiving essential documents required after the completion of a clinical trial, in compliance with ICH E6 §8, FDA, EMA, CDSCO, and WHO GCP requirements. It covers trial closeout reports, clinical study reports, IP destruction certificates, financial reconciliations, and archiving processes.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Essential Documents After Trial (ICH E6 §8)

Purpose

The purpose of this SOP is to define standardized procedures for collecting, filing, and archiving essential documents after the completion of a clinical trial. These records demonstrate that the trial was conducted in compliance with GCP, regulatory requirements, and ethical standards, and that data generated is credible and verifiable.

Scope

This SOP applies to sponsors, CROs, investigators, QA, and TMF administrators involved in the closeout, filing, and archiving of essential trial documents. It covers site closeout, final trial reporting, investigational product (IP) destruction, financial reconciliation, and TMF/ISF archiving.

Responsibilities

• Sponsor: Ensures all essential documents are filed, reconciled, and archived.
• CRO: May handle closeout activities under sponsor oversight.
• Investigator: Provides final subject-level records and site closeout report.
• QA: Audits TMF and ISF for completeness at closeout.
• TMF Administrator: Reconciles and files documents, coordinates archiving.
• Regulatory Affairs: Submits final reports to authorities and ECs.

Accountability

The sponsor is accountable for the completeness and retention of essential documents after the trial. The PI is accountable for site-level closeout documentation. QA is accountable for verifying inspection readiness before archiving.

Procedure

1. Site Closeout Documentation
1.1 File Site Closeout Visit Report prepared by CRA.
1.2 File Investigator’s Final Report/Letter of Completion to EC/IRB.
1.3 File EC/IRB notification of trial closure.

2. Final Clinical Trial Reports
2.1 File Clinical Study Report (CSR) prepared per ICH E3 guidelines.
2.2 File statistical analysis reports and listings.
2.3 File data transfer certificates and database lock confirmation.

3. Investigational Product Documentation
3.1 File IP accountability reconciliation logs.
3.2 File IP destruction certificates signed by pharmacist and witness.
3.3 File correspondence regarding IP return or destruction.

4. Safety Documentation
4.1 File final SAE/SUSAR listings.
4.2 File final DSUR/PSUR submissions.
4.3 File pharmacovigilance closeout summary.

5. Financial and Administrative Documentation
5.1 File final financial reconciliation records.
5.2 File final CRO/vendor invoices and payment records.
5.3 File insurance documentation covering trial period.

6. Subject Documentation
6.1 File final subject status logs (completed, withdrawn, lost to follow-up).
6.2 File subject compensation/reimbursement records.

7. Archiving
7.1 TMF/ISF must be reconciled and complete before archiving.
7.2 Archive essential documents in secure, access-controlled facility.
7.3 Retain for a minimum of 15 years or per jurisdictional requirement.
7.4 Document archiving in TMF Archiving Log (Annexure-1).

Abbreviations

• SOP: Standard Operating Procedure
• TMF/ISF: Trial Master File / Investigator Site File
• PI: Principal Investigator
• CRA: Clinical Research Associate
• CSR: Clinical Study Report
• IP: Investigational Product
• SAE: Serious Adverse Event
• SUSAR: Suspected Unexpected Serious Adverse Reaction
• DSUR/PSUR: Development Safety Update Report / Periodic Safety Update Report

Documents

1. TMF Archiving Log (Annexure-1)
2. Site Closeout Checklist (Annexure-2)
3. IP Destruction Certificate (Annexure-3)
4. Final Subject Status Log (Annexure-4)
5. Financial Reconciliation Log (Annexure-5)

References

• ICH E6(R2/R3) – Essential Documents After Trial
• FDA – TMF and Clinical Trial Documentation
• EMA – Post-Trial Documentation Guidance
• CDSCO – Clinical Trial Closure Requirements
• WHO – Archiving and Retention of Essential Documents

Version: 1.0

Approval Section

Annexures

Annexure-1: TMF Archiving Log

Annexure-2: Site Closeout Checklist

Annexure-3: IP Destruction Certificate

Annexure-4: Final Subject Status Log

Annexure-5: Financial Reconciliation Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-essential-documents-during-trial-ich-e6-section-8”
},
“headline”: “SOP for Essential Documents During Trial (ICH E6 §8)”,
“description”: “This SOP defines the essential documents required to be filed and maintained during the conduct of a clinical trial, in compliance with ICH E6 §8 and global regulatory requirements, including protocols, approvals, monitoring reports, safety records, IP logs, consent forms, and training documentation.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Essential Documents During Trial (ICH E6 §8)

Purpose

The purpose of this SOP is to define the process for collecting, filing, and maintaining essential documents during the conduct of a clinical trial, as per ICH E6 §8 requirements. These documents collectively enable the evaluation of trial conduct and ensure compliance with GCP, regulatory expectations, and subject protection.

Scope

This SOP applies to sponsors, CROs, investigators, site staff, and QA responsible for maintaining essential documents in the TMF and ISF during the trial. It covers monitoring reports, approvals, informed consent forms, IP accountability logs, correspondence, safety reporting, and other trial-related documentation.

Responsibilities

• Sponsor: Ensures TMF is complete and contemporaneous.
• CRO: Maintains documents delegated by sponsor under oversight.
• Investigator: Maintains ISF and subject-level essential documents.
• CRA: Collects and files monitoring reports, logs, and site-level records.
• QA: Audits TMF and ISF to ensure inspection readiness.
• TMF Administrator: Classifies, indexes, and files documents with quality checks.

Accountability

The Head of Clinical Operations is accountable for overall TMF maintenance during the trial. Investigators are accountable for ISF completeness. QA is accountable for verifying inspection readiness.

Procedure

1. Protocol and Amendments
1.1 File final approved protocol and all subsequent amendments.
1.2 Ensure all amendments are approved by EC/IRB and regulatory authorities.

2. Informed Consent Documentation
2.1 File signed informed consent forms (ICFs) for each subject.
2.2 Ensure contemporaneous version control and language approvals.
2.3 Maintain ICF Filing Log (Annexure-1).

3. Investigator and Site Documentation
3.1 File updated CVs and training certificates of PI and site staff.
3.2 File updated Delegation of Authority Logs.
3.3 File Investigator communication with sponsor/CRO.

4. Monitoring Documentation
4.1 File monitoring visit reports, follow-up letters, and responses.
4.2 Ensure reconciliation between reports and trial activities.
4.3 Maintain Monitoring Report Log (Annexure-2).

5. Investigational Product Documentation
5.1 File IP accountability logs, receipts, dispensing records, and destruction logs.
5.2 File temperature logs and excursion reports.
5.3 Maintain IP Accountability Log (Annexure-3).

6. Safety Documentation
6.1 File SAE reports, SUSAR submissions, and follow-up documentation.
6.2 File DSUR/PSUR submissions and safety committee communications.
6.3 Maintain Safety Reporting Log (Annexure-4).

7. Subject-Level Documentation
7.1 File subject ID logs, screening and enrolment logs.
7.2 File eligibility verification checklists.
7.3 Maintain Subject Tracking Log (Annexure-5).

8. Correspondence and Communication
8.1 File essential correspondence with regulators, ECs/IRBs, CROs, and vendors.
8.2 File minutes of meetings and teleconferences.
8.3 Maintain Correspondence Log (Annexure-6).

9. Training and Qualification
9.1 File training records for staff joining during the trial.
9.2 Maintain GCP training certificates.
9.3 Maintain Training Record Log (Annexure-7).

10. Quality Control
10.1 Perform monthly QC checks on TMF/ISF.
10.2 Document findings in TMF QC Log (Annexure-8).
10.3 Correct discrepancies within 10 working days.

Abbreviations

• SOP: Standard Operating Procedure
• TMF/ISF: Trial Master File / Investigator Site File
• PI: Principal Investigator
• CRA: Clinical Research Associate
• QA: Quality Assurance
• EC/IRB: Ethics Committee / Institutional Review Board
• SAE: Serious Adverse Event
• SUSAR: Suspected Unexpected Serious Adverse Reaction
• DSUR/PSUR: Development Safety Update Report / Periodic Safety Update Report

Documents

1. ICF Filing Log (Annexure-1)
2. Monitoring Report Log (Annexure-2)
3. IP Accountability Log (Annexure-3)
4. Safety Reporting Log (Annexure-4)
5. Subject Tracking Log (Annexure-5)
6. Correspondence Log (Annexure-6)
7. Training Record Log (Annexure-7)
8. TMF QC Log (Annexure-8)

References

• ICH E6(R2/R3) – Essential Documents During Trial
• FDA – TMF Maintenance Guidance
• EMA – TMF and ISF Inspection Guidance
• CDSCO – Essential Documents Filing
• WHO – GCP Essential Documents

Version: 1.0

Approval Section

Annexures

Annexure-1: ICF Filing Log

Annexure-2: Monitoring Report Log

Annexure-3: IP Accountability Log

Annexure-4: Safety Reporting Log

Annexure-5: Subject Tracking Log

Annexure-6: Correspondence Log

Annexure-7: Training Record Log

Annexure-8: TMF QC Log

Revision History

For more SOPs visit: Pharma SOP

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-essential-documents-before-trial-ich-e6-section-8”
},
“headline”: “SOP for Essential Documents Before Trial (ICH E6 §8)”,
“description”: “This SOP defines the required essential documents to be filed before the initiation of a clinical trial, in compliance with ICH E6 §8 and regulatory requirements of FDA, EMA, CDSCO, and WHO. It includes procedures for filing protocols, approvals, IB, consent templates, CVs, training records, contracts, and regulatory correspondence.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Essential Documents Before Trial (ICH E6 §8)

Purpose

The purpose of this SOP is to describe the management, filing, and verification of essential documents required before the initiation of a clinical trial, in accordance with ICH E6 §8, GCP, and global regulatory authority expectations. These documents collectively demonstrate trial preparation, regulatory compliance, and readiness for initiation.

Scope

This SOP applies to all clinical trials sponsored or managed by the organization and covers sponsor, CRO, investigator site, and vendor responsibilities for generating, collecting, and filing essential documents before trial initiation. It includes regulatory approvals, contracts, study-specific records, and readiness assessments.

Responsibilities

• Sponsor: Ensures all pre-trial essential documents are collected, filed, and verified.
• CRO: Collects and files documents on behalf of sponsor when delegated.
• Investigator: Provides site-level documents such as CVs, training records, and ISF setup.
• QA: Conducts pre-trial TMF review and audit readiness check.
• Regulatory Affairs: Provides regulatory submissions and approvals.
• Clinical Operations: Ensures all contracts, logs, and templates are filed.

Accountability

Sponsor is accountable for ensuring completeness and accuracy of essential documents before trial start. QA is accountable for verifying readiness, while CRO and investigators are responsible for document provision.

Procedure

1. Protocol and Related Documents
1.1 File final protocol, protocol amendments (if any), and synopsis in TMF/ISF.
1.2 File protocol signature page with sponsor, investigator, and approval authority signatures.
1.3 File Investigator Brochure (IB) and any updates.

2. Regulatory and Ethics Approvals
2.1 File EC/IRB approval letter for protocol, informed consent, and recruitment materials.
2.2 File regulatory authority approvals (e.g., IND, CTA, CTN approval letters).
2.3 File correspondence with authorities in Regulatory Correspondence Log (Annexure-1).

3. Informed Consent Templates
3.1 File approved informed consent form templates, including local language versions.
3.2 Ensure that assent forms for pediatric trials are included.
3.3 Maintain Consent Template Log (Annexure-2).

4. Site and Investigator Documentation
4.1 File CVs and medical licenses for PI and sub-investigators.
4.2 File GCP and protocol training certificates.
4.3 File Delegation of Authority Log (Annexure-3).

5. Contracts and Agreements
5.1 File CRO, vendor, and site contracts with scope of work, timelines, and compliance clauses.
5.2 File financial disclosure forms of investigators.
5.3 File insurance and indemnity certificates.

6. Facility and Laboratory Documentation
6.1 File site qualification checklist and initiation visit reports.
6.2 File laboratory certifications, accreditations, and normal ranges.
6.3 File equipment calibration and maintenance certificates.

7. Investigational Product Documentation
7.1 File regulatory approvals for labeling and import/export licenses.
7.2 File IP labeling and accountability plan.
7.3 File IP shipping and storage arrangements documentation.

8. Verification and Quality Control
8.1 TMF Administrator maintains Essential Documents Checklist (Annexure-4).
8.2 QA verifies all documents are filed before initiation meeting.
8.3 Missing documents must be tracked in Pre-Trial Document Gap Log (Annexure-5).

Abbreviations

• SOP: Standard Operating Procedure
• TMF/ISF: Trial Master File / Investigator Site File
• PI: Principal Investigator
• EC/IRB: Ethics Committee / Institutional Review Board
• IB: Investigator Brochure
• CRO: Contract Research Organization
• IP: Investigational Product
• QA: Quality Assurance

Documents

1. Regulatory Correspondence Log (Annexure-1)
2. Consent Template Log (Annexure-2)
3. Delegation of Authority Log (Annexure-3)
4. Essential Documents Checklist (Annexure-4)
5. Pre-Trial Document Gap Log (Annexure-5)

References

• ICH E6(R2/R3) – Section 8 Essential Documents
• FDA – Essential Documents Before Trial
• EMA – GCP Inspection Guidance
• CDSCO – Essential Documents Checklist
• WHO – Pre-Trial Documentation Requirements

Version: 1.0

Approval Section

Annexures

Annexure-1: Regulatory Correspondence Log

Annexure-2: Consent Template Log

Annexure-3: Delegation of Authority Log

Annexure-4: Essential Documents Checklist

Annexure-5: Pre-Trial Document Gap Log

Revision History

For more SOPs visit: Pharma SOP